VC
Value Add VC
⚡HomePulse⚡Helpful Apps📝Blog
Illustration for: 2026's IPO Window Is Open, But Pricing Is Cut
Value Add VC/Pulse/IPO

2026's IPO Window Is Open, But Pricing Is Cut

Nearly every major consumer and industrial IPO this cycle has priced well below the valuation chatter that preceded it, despite a record first half for new listings.

$129.3B, record
H1 2026 Nasdaq listings
~$8B vs $10-12B
Jersey Mike's actual vs chatter
~$1B vs $2.5-3B
Reformation vs. Cava/Sweetgreen
~50% discount
Shein target vs. peak
TC
Trace Cohen
Early-stage VC & angel · Founder, New York Venture Partners
July 27, 2026
1 min read
ShareXLinkedInEmail

THE RUNDOWN

1

Nasdaq's record $129.3 billion in H1 2026 listings shows the IPO window is genuinely open, but pricing has been conservative across nearly every sector

2

Jersey Mike's cut from $10-12 billion in early chatter to an actual ~$8 billion range; Reformation's ~$1 billion target trails Cava's $2.5 billion and Sweetgreen's $3 billion prior-cycle debuts

3

General Fusion's GFUZ has already cooled from its $14.85 debut high to around $13.60, and Shein is targeting roughly half its ~$100 billion private peak valuation

4

Even CXMT's blockbuster 471% debut priced conservatively at 8.66 yuan before the market repriced it upward, showing underwriters -- not investor demand -- are setting cautious initial numbers

TC

The VC Read · Trace's Take

Trace Cohen

Every GP still marking portfolio companies at 2024-2025 private valuations needs to internalize this pattern: 2026's public markets are discounting nearly everything at IPO, not paying a premium the way 2021 did. Treat an eventual IPO as a markdown event to plan for, not a mark-preserving exit to assume -- the data this week says otherwise across consumer, deep-tech, and Chinese listings alike.

IPO Wave 2026 → IPO Scorecard →

Analysis

The 2026 IPO window is genuinely open -- Nasdaq reported a record $129.3 billion raised in new listings during the first half of the year -- but nearly every consumer and industrial debut this cycle has priced well below the valuation chatter that preceded it, a pattern worth naming explicitly as this week's deals come to market.

Jersey Mike's roadshow is a clean example: early reports floated a $10-12 billion valuation, but the actual price range of $21-25 per share implies a valuation closer to $8 billion. Reformation's $15-17 per-share range implies roughly $1 billion, a fraction of what Cava commanded at its 2023 debut ($2.5 billion) and Sweetgreen at its 2021 listing ($3 billion) -- both smaller, less-established brands than Jersey Mike's franchise footprint, priced richer by public markets in prior cycles.

The pattern extends beyond consumer names: General Fusion's GFUZ has already cooled from its $14.85 debut-day high to around $13.60 two weeks later, and Shein's own prospectus targets $40-50 billion, roughly half its approximately $100 billion private peak. Even CXMT's explosive 471% debut this week, while a headline win, still priced its actual IPO conservatively at 8.66 yuan per share before the market repriced it upward -- underwriters, not investor enthusiasm, set the initial number low.

The consistent thread is that bankers are pricing conservatively across nearly every category this cycle, whether the underlying story is consumer retail, deep-tech, or Chinese memory -- a sharp contrast with 2021-era IPO pricing, where growth-stage private valuations were frequently exceeded on debut, not undercut.

For GPs and later-stage investors, the practical implication is that private marks set during 2024-2025 fundraising rounds should not be assumed to hold at IPO -- across nearly every sector, 2026's public market is demanding a real discount to recent private pricing before it will buy in, and portfolio construction should account for that markdown risk explicitly rather than treating an eventual IPO as a mark-preserving exit.

ShareXLinkedInEmail

Analysis and editorial commentary by Value Add Pulse.

← Back to Pulse

THE WIRE in your inbox— Tech, startup & VC news with Trace's take. Free, no spam.

Read Next

IPO· Jul 27, 2026

CXMT Rockets 466% in STAR Market Trading Debut

Illustration for: CXMT Rockets 466% in STAR Market Trading Debut
IPO$8.6B Raised, +471%

CXMT Rockets 466% in STAR Market Trading Debut

Chinese memory maker CXMT surged as much as 471% in its Shanghai STAR Market trading debut, instantly becoming mainland China's most valuable listed company.

IPO· Jul 27, 2026

Shein's IPO Prospectus Reveals Slowing Growth

Illustration for: Shein's IPO Prospectus Reveals Slowing Growth
IPO$40B-$50B Target

Shein's IPO Prospectus Reveals Slowing Growth

Shein's Hong Kong IPO prospectus disclosed slowing revenue growth and a swing to a quarterly loss, complicating its push for a $40-50 billion valuation.

IPO· Jul 27, 2026

Apnimed Launches $150M IPO for Sleep Apnea Pill

Illustration for: Apnimed Launches $150M IPO for Sleep Apnea Pill
IPO$150M-$160M IPO

Apnimed Launches $150M IPO for Sleep Apnea Pill

Apnimed launched a $150-160 million IPO for a pill that could become the first FDA-approved treatment for obstructive sleep apnea.

@Trace_Cohen·t@nyvp.com